Jade Biosciences, Inc. Earnings Per Share (Diluted)
Jade Biosciences, Inc. (JBIO) reported Earnings Per Share (Diluted) of -$0.76 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-10
- Jade Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.76.
- Jade Biosciences, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.57.
- Jade Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.50.
- Jade Biosciences, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.48.
- Jade Biosciences, Inc. earnings per share, diluted for fiscal 2025 was -$3.19.
- Jade Biosciences, Inc. earnings per share, diluted for fiscal 2024 was -$2.44.
- Jade Biosciences, Inc. earnings per share, diluted for fiscal 2023 was -$2.87.
- Jade Biosciences, Inc. earnings per share, diluted for fiscal 2022 was -$2.10.
| Period end | Earnings Per Share, Diluted 0 month | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.76 10-Q · filed 2026-08-10 | -$1.33 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | -$0.57 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-03-06 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-03-06 | -$3.19 10-K · filed 2026-03-06 | |||
| 2025-09-30 | -$0.48 10-Q · filed 2025-11-14 | -$3.08 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | -$0.86 10-Q · filed 2026-08-10 | -$3.45 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | -$12.10 10-Q · filed 2026-05-07 | -$0.09 10-Q · filed 2025-04-25 | -$21.64 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$26.98 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||
| 2024-12-31 | -$9.54 derived: net income ÷ weighted average shares · filed 2026-03-06 | -$14.89 10-K · filed 2026-03-06 | -$2.44 10-K · filed 2025-03-27 | |||
| 2024-09-30 | -$5.16 10-Q · filed 2025-11-14 | -$0.56 10-Q · filed 2024-11-12 | -$2.25 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | -$0.19 10-Q · filed 2025-08-13 | -$0.86 10-Q · filed 2024-08-12 | -$1.68 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | -$0.83 10-Q · filed 2025-04-25 | |||||
| 2023-12-31 | -$2.87 10-K · filed 2025-03-27 | |||||
| 2023-09-30 | -$0.71 10-Q · filed 2024-11-12 | -$2.13 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$0.76 10-Q · filed 2024-08-12 | -$1.42 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$0.67 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | -$2.10 10-K · filed 2024-03-25 | |||||
| 2022-09-30 | -$0.56 10-Q · filed 2023-11-13 | -$1.49 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$0.49 10-Q · filed 2023-08-14 | -$0.94 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | -$0.45 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | -$1.87 10-K · filed 2023-03-29 | |||||
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-14 | -$1.80 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |